INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Derivative conversionVerified data

Rachlin Evan Lockwood reported IAM

Director · Iambic Therapeutics, Inc. · Iambic Therapeutics, Inc. — Series B-3 Convertible Preferred Stock

Side
C
Value
—
Shares
306.7K
Price
—
Executed
Oct 16, 2026
Disclosed
Oct 19, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Oct 16 executedOct 19, 2026 disclosed

IAM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Derivative conversion — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IAM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    410.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    2.00M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    57.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.14M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    731.2K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    122.7K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    VJ
    Vogelstein R JacobDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    17
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    410.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    49
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Open-market purchase
    		BUY$11.50M
    718.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.15M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RL
    Rachlin Evan LockwoodDirector
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    57.8K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    2.00M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.46M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    742.5K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    1.14M sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    9
    Catalio Capital Management, LP10% Owner
    IAMIambic Therapeutics, Inc.
    Derivative conversion
    		C—
    731.2K sh
    		Oct 16, 2026Oct 19, 2026
    traded Oct 16, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002151678-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 16, 2026
    Published
    Oct 19, 2026
    Ingested by INSIDER
    Nov 5, 02:10 UTC
    Last re-read
    Nov 5, 02:10 UTC

    Extracted facts

    Filer
    Rachlin Evan Lockwood
    Role
    Director
    Transaction
    Derivative conversionAs filed: “C”
    Asset
    Iambic Therapeutics, Inc. — Series B-3 Convertible Preferred Stock
    Ticker
    IAM
    Shares
    306.7K
    Price per share
    $0
    Execution date (reported)
    Oct 16, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    3

    What this establishes

    Rachlin Evan Lockwood filed this Form 4 reporting a derivative conversion of IAM on Oct 16, 2026. It became public on Oct 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Rachlin Evan Lockwoodcik:0002151678
    Issuer
    Iambic Therapeutics, Inc.cik:0001997038

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.